{
  "meta": {
    "title": "Antiarrhythmic drugs",
    "url": "https://brainandscalpel.vercel.app/antiarrhythmic-drugs-f885b4ac-9c7cd6.html",
    "scrapedAt": "2025-12-01T05:55:19.274Z",
    "type": "article"
  },
  "content": "\n                <div><h1>Cardiac action potential</h1><p>The cardiac action potential is created by ion channels that drive electrical current through the myocardium and facilitate the coordinated contraction of the atria and ventricles; sodium (Na<font size=\"2\"><sup>+</sup></font>), calcium (Ca<font size=\"2\"><sup>2+</sup></font>), and potassium (K<font size=\"2\"><sup>+</sup></font>) are the major ions involved.&nbsp; The cardiac action potential differs between 2 distinct types of myocardia (\n                                </p><div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L11401.jpg\" alt=\"figure 1\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 1</div>\n                                </div>\n                                ):<p></p><h2>Nonpacemaker cells</h2><p><strong>Nonpacemaker cells</strong>, which include the cells of the atrial and ventricular myocardium, are fast-conducting.&nbsp; The nonpacemaker action potential is composed of the following phases:</p><ul class=\"article-body-unordered-list\"><li><strong>Phase 0 (rapid depolarization)</strong>:&nbsp; Occurs when the resting membrane potential reaches threshold.&nbsp; It involves <strong>rapid Na</strong><font size=\"2\"><sup><strong>+</strong></sup></font> <strong>entry into the cell</strong> due to the activation and opening of voltage-dependent Na<font size=\"2\"><sup>+</sup></font> channels.</li><li><strong>Phase 1 (early repolarization)</strong>:&nbsp; Results primarily from the activation of transient <strong>outward K</strong><font size=\"2\"><sup><strong>+</strong></sup></font> <strong>currents</strong> along with a rapid decline of inward Na<font size=\"2\"><sup>+</sup></font> current.</li><li><strong>Phase 2 (plateau phase)</strong>:&nbsp; Characterized by a <strong>stable</strong> membrane potential due to a balance of late inward Ca<font size=\"2\"><sup>2+</sup></font> current (L-type channels) and outward K<font size=\"2\"><sup>+</sup></font> current.</li><li><strong>Phase 3 (late repolarization)</strong>:&nbsp; Results from the opening of additional K<font size=\"2\"><sup>+</sup></font> channels (delayed-rectifier K<font size=\"2\"><sup>+</sup></font> currents) and <strong>continued efflux of K</strong><font size=\"2\"><sup><strong>+</strong></sup></font> from the cell.&nbsp; This is in conjunction with the decay of inward Ca<font size=\"2\"><sup>2+</sup></font> current.</li><li><strong>Phase 4 (resting)</strong>:&nbsp; Characterized by normal resting membrane potential between <strong>‚àí80 and ‚àí95 mV</strong> (near the equilibrium potential of K<font size=\"2\"><sup>+</sup></font>).&nbsp; It is maintained by <strong>outward K</strong><font size=\"2\"><sup><strong>+</strong></sup></font> <strong>flow</strong> through K<font size=\"2\"><sup>+</sup></font> leak channels that are open at rest.&nbsp; The Na<font size=\"2\"><sup>+</sup></font>-K<font size=\"2\"><sup>+</sup></font>-ATPase pump allows the K<font size=\"2\"><sup>+</sup></font> and Na<font size=\"2\"><sup>+</sup></font> gradients to be maintained across the membrane.</li></ul><h2>Pacemaker cells</h2><p>Pacemaker cells, which include the cells of the sinoatrial (SA) and atrioventricular (AV) nodes, are relatively slow-conducting and are unique in that they exhibit <strong>automaticity</strong> (an inherent ability to depolarize without external influence).&nbsp; The pacemaker action potential is composed of the following phases:</p><ul class=\"article-body-unordered-list\"><li><strong>Phase 4 (spontaneous depolarization)</strong>:&nbsp; Begins after hyperpolarization (membrane potential more negative than the resting potential) triggers the opening of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that allow the slow <strong>influx of Na</strong><font size=\"2\"><sup><strong>+</strong></sup></font> <strong>(\"funny current\")</strong>.&nbsp; Once the membrane potential becomes more positive, T-type (transient) Ca<font size=\"2\"><sup>2+</sup></font> channels open, allowing Ca<font size=\"2\"><sup>2+</sup></font> influx to contribute to depolarization.&nbsp; As the pacemaker cell approaches depolarization threshold, L-type (long-lasting) Ca<font size=\"2\"><sup>2+</sup></font> channels begin to open, which further increases <strong>Ca</strong><font size=\"2\"><sup><strong>2+</strong></sup></font> <strong>influx</strong> and allows the threshold to be reached.</li><li><strong>Phase 0 (upstroke)</strong>:&nbsp; Results from the continued opening of L-type Ca<font size=\"2\"><sup>2+</sup></font> channels and marked <strong>influx of Ca</strong><font size=\"2\"><sup><strong>2+</strong></sup></font>.&nbsp; Compared to nonpacemaker tissue, the action potential upstroke in pacemaker tissue is much slower and transitions gradually from phase 4 due to the relatively slow influx of Ca<font size=\"2\"><sup>2+</sup></font> into the cell.</li><li><strong>Phase 3 (repolarization)</strong>:&nbsp; Results from the opening of K<font size=\"2\"><sup>+</sup></font> channels and <strong>efflux of K</strong><font size=\"2\"><sup><strong>+</strong></sup></font> from the cell in conjunction with the closure of L-type Ca<font size=\"2\"><sup>2+</sup></font> channels, making the resting membrane potential more negative, with eventual hyperpolarization.</li></ul><h1>ECG manifestations of the cardiac action potential</h1><p>An ECG is a tracing of electrical current as it travels through the heart; therefore, the major components of an ECG tracing correspond with key portions of the cardiac action potential (\n                                </p><div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L61009.jpg\" alt=\"figure 2\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 2</div>\n                                </div>\n                                ).<p></p><h2>P wave and PR interval</h2><ul class=\"article-body-unordered-list\"><li>The <strong>P wave</strong> on ECG represents atrial depolarization.</li><li>The <strong>PR interval</strong> is the period from the beginning of atrial depolarization (start of the P wave) to the beginning of ventricular depolarization (start of the QRS complex).&nbsp; The PR interval is determined primarily by the rate of Ca<font size=\"2\"><sup>2+</sup></font> influx through L-type Ca<font size=\"2\"><sup>2+</sup></font> channels during phase 0 of the pacemaker (SA and AV node) action potential.</li><li>Atrial repolarization occurs during ventricular depolarization and is electrically silent on ECG.</li></ul><h2>QRS complex</h2><ul class=\"article-body-unordered-list\"><li>The <strong>QRS complex</strong> on ECG represents ventricular depolarization.&nbsp; The width (or duration) of the QRS complex is determined primarily by the rate of <strong>Na</strong><font size=\"2\"><sup><strong>+</strong></sup></font> <strong>influx</strong> during phase 0 of the nonpacemaker (ventricular cardiomyocyte) action potential.</li><li>The <strong>QT interval</strong> on ECG represents the duration of the ventricular action potential (ie, ventricular depolarization and repolarization), and is determined primarily by the rate of <strong>K</strong><font size=\"2\"><sup><strong>+</strong></sup></font> <strong>efflux</strong> during phase 3 of the nonpacemaker action potential.</li></ul><h1>Vaughan Williams antiarrhythmic drug classifications</h1><p>Antiarrhythmic drugs are commonly organized into the following classes based on their primary mechanism of action (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/80876.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">üìä</span> View Table: table 1\n                                    </a>\n                                </div>\n                                ).<p></p><h2>Class I antiarrhythmics</h2><p>In general, class I antiarrhythmics act by blocking <strong>voltage-gated Na</strong><font size=\"2\"><sup><strong>+</strong></sup></font> <strong>channels</strong> in <strong>nonpacemaker cells</strong>, inhibiting the initial ventricular depolarization <strong>(phase 0)</strong> and prolonging the QRS duration.&nbsp; They bind within the pore of the Na<font size=\"2\"><sup>+</sup></font> channels during the open/inactivated states and dissociate during the resting state (\n                                </p><div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L33430.jpg\" alt=\"figure 3\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 3</div>\n                                </div>\n                                ) (state-dependent binding).&nbsp; As a result, Na‚Å∫ channel blockade becomes more pronounced at faster heart rates, when channels spend more time in the open/inactivated states‚Äîa phenomenon known as <strong>use dependence</strong> (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L33431.jpg\" alt=\"figure 4\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 4</div>\n                                </div>\n                                ).<p></p><p>Although class I antiarrhythmics are categorized primarily as Na<font size=\"2\"><sup>+</sup></font> channel blockers, they differ in binding strength, dissociation speed, and effects on K‚Å∫ channels, leading to distinct electrophysiologic and clinical profiles (\n                                </p><div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L125256.png\" alt=\"figure 5\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 5</div>\n                                </div>\n                                ):<p></p><ul class=\"article-body-unordered-list\"><li>Class IA drugs (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L125257.png\" alt=\"figure 6\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 6</div>\n                                </div>\n                                ) have <strong>intermediate/moderate Na</strong><font size=\"2\"><sup><strong>+</strong></sup></font> <strong>channel</strong> blocking activity, which causes a moderate slowing (slope reduction) of phase 0 (with moderate use dependence) and results in an increased QRS duration.&nbsp; Concurrent <strong>K</strong><font size=\"2\"><sup><strong>+</strong></sup></font> <strong>channel blockade</strong> lengthens phase 3 to increase action potential duration.&nbsp; Class IA drugs include:<ul class=\"article-body-unordered-list\"><li>Procainamide.</li><li>Disopyramide.</li><li>Quinidine.</li></ul></li><li>Class IB drugs (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L125258.png\" alt=\"figure 7\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 7</div>\n                                </div>\n                                ) cause <strong>weak Na</strong><font size=\"2\"><sup><strong>+</strong></sup></font> <strong>channel blockade</strong> with rapid dissociation, creating a slight phase 0 slope reduction with minimal use dependence and no significant effect on the QRS duration.&nbsp; Inhibition of \"plateau\" Na<font size=\"2\"><sup>+</sup></font> current shortens phase 3 to decrease action potential duration.&nbsp; Class IB drugs preferentially target <strong>ischemic myocardium</strong>, where resting membrane potential is less negative, delaying channel recovery (from inactivated to resting) and increasing drug binding.&nbsp; Class IB drugs include:<ul class=\"article-body-unordered-list\"><li>Lidocaine.</li><li>Mexiletine.</li></ul></li><li>Class IC drugs (\n                                <div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L125259.png\" alt=\"figure 8\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 8</div>\n                                </div>\n                                ) are <strong>strong Na</strong><font size=\"2\"><sup><strong>+</strong></sup></font> <strong>channel blockers</strong> with slow dissociation, producing substantial phase 0 slope reduction and increased QRS duration in a rate-dependent manner (high use dependence).&nbsp; They are useful in <strong>terminating tachyarrhythmias</strong>.&nbsp; However, their prominent use-dependent effects can cause an excessive delay in conduction speed that can <strong>promote arrhythmias</strong> (eg, ventricular tachycardia), especially in patients with ischemic or structural heart disease.&nbsp; Class IC drugs include<ul class=\"article-body-unordered-list\"><li>Flecainide.</li><li>Propafenone.</li></ul></li></ul><p>The effects of the class I antiarrhythmic subtypes are summarized in this table (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/81487.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">üìä</span> View Table: table 2\n                                    </a>\n                                </div>\n                                ).<p></p><h2>Class II antiarrhythmics (beta blockers)</h2><p>Class II antiarrhythmics function by blocking sympathetic drive to <strong>pacemaker cells</strong>, reducing intracellular cyclic AMP and leading primarily to the slowing of <strong>phase 4</strong> (and also of phase 0).&nbsp; This results in a decreased rate of SA node firing and decreased AV node conduction velocity.&nbsp; The slowed AV node conduction lengthens the PR interval.&nbsp; <strong>Beta blockers</strong> constitute the entirety of the class II antiarrhythmics (drugs ending in \"-lol\"); notable examples include:</p><ul class=\"article-body-unordered-list\"><li>Metoprolol.</li><li>Atenolol.</li><li>Bisoprolol.</li><li>Esmolol.</li></ul><h2>Class III antiarrhythmics</h2><p>Class III antiarrhythmics function by blocking voltage-gated K<font size=\"2\"><sup>+</sup></font> channels in <strong>nonpacemaker cells</strong>, resulting in the slowing of ventricular repolarization <strong>(phase 3)</strong>.&nbsp; Class III antiarrhythmics include:</p><ul class=\"article-body-unordered-list\"><li>Amiodarone.</li><li>Dronedarone.</li><li>Dofetilide.</li><li>Ibutilide.</li><li>Sotalol.</li></ul><h2>Class IV antiarrhythmics (nondihydropyridine Ca<font size=\"2\"><sup>2+</sup></font> channel blockers)</h2><p>Class IV antiarrhythmics function by blocking Ca<font size=\"2\"><sup>2+</sup></font> channels in <strong>pacemaker cells</strong>, leading to the slowing of <strong>phase 0</strong>.&nbsp; Similar to the class II effect, this leads to a decreased rate of SA node firing and decreased AV node conduction velocity.&nbsp; The slowed AV node conduction lengthens the PR interval.&nbsp; <strong>Nondihydropyridine calcium channel blockers</strong> (CCBs) constitute the entirety of the class IV antiarrhythmics; notable examples include:</p><ul class=\"article-body-unordered-list\"><li>Verapamil.</li><li>Diltiazem.</li></ul><p>(Dihydropyridine CCBs, such as amlodipine, act primarily on L-type Ca<font size=\"2\"><sup>2+</sup></font> channels in vascular smooth muscle, leading to peripheral vasodilation and making them useful for hypertension; in contrast, nondihydropyridine CCBs preferentially affect the myocardium and nodal tissue, making them effective as antiarrhythmics.)</p><h2>Drugs with multiple class effects</h2><ul class=\"article-body-unordered-list\"><li><strong>Amiodarone</strong>:&nbsp; In addition to predominant class III antiarrhythmic properties, amiodarone also has properties of class I, II, and IV antiarrhythmics, as described below:<ul class=\"article-body-unordered-list\"><li>Class I effect:&nbsp; Amiodarone somewhat inhibits the Na<font size=\"2\"><sup>+</sup></font> channels responsible for phase 0 of the ventricular action potential.&nbsp; This slows ventricular depolarization and increases the duration of the QRS complex.</li><li>Class II and IV effects:&nbsp; Amiodarone has beta-blocking properties that inhibit sympathetic stimulation of pacemaker cells (class II effect) and also directly inhibits the slow L-type Ca<font size=\"2\"><sup>2+</sup></font> channels responsible for depolarization of the SA and AV nodes (class IV effect).&nbsp; Both effects lengthen the PR interval.</li></ul></li><li><strong>Sotalol</strong>:&nbsp; In addition to predominant class III antiarrhythmic properties, sotalol also has class II effects (beta-blocking properties) that lengthen the PR interval and slow the sinus rate.</li></ul><h2>Summary of ECG effects of antiarrhythmic drugs</h2><p>The ECG effects of drugs from the various antiarrhythmic classes, as well as those of specific drugs with multiple class effects, are summarized here (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/60911.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">üìä</span> View Table: table 3\n                                    </a>\n                                </div>\n                                ).<p></p><h2>Other antiarrhythmics with nonclass effects</h2><p>Both <strong>adenosine</strong> and <strong>digoxin</strong> affect the pacemaker cell action potential through mechanisms that differ somewhat from class II and class IV antiarrhythmics (\n                                </p><div class=\"my-8\">\n                                    <img src=\"https://www.uworld.com/media/L125632.jpg\" alt=\"figure 9\" class=\"w-full rounded-lg border border-white border-opacity-20 shadow-lg\">\n                                    <div class=\"text-sm text-center text-white text-opacity-60 mt-2 italic\">figure 9</div>\n                                </div>\n                                ):<p></p><ul class=\"article-body-unordered-list\"><li>Adenosine binds to A1 receptors in the AV node to inhibit adenylyl cyclase and decrease cyclic AMP activity.&nbsp; Digoxin stimulates muscarinic receptors in the AV node to increase vagal tone, inhibit adenylyl cyclase, and decrease cyclic AMP activity.&nbsp; Reduced cyclic AMP activity slows phase 4 and phase 0 to decrease conduction velocity and increase the AV node refractory period (similar net effects to beta blockers).</li><li>Adenosine and digoxin also stimulate inward rectifier K<font size=\"2\"><sup>+</sup></font> channels to hyperpolarize the pacemaker action potential and suppress depolarization (unlike beta blockers).</li></ul><h1>Mechanisms of antiarrhythmic effects</h1><h2>Mechanisms of tachyarrhythmias</h2><p>The 3 major mechanisms through which cardiac tachyarrhythmias develop are (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/116989.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">üìä</span> View Table: table 4\n                                    </a>\n                                </div>\n                                ):<p></p><ul class=\"article-body-unordered-list\"><li><strong>Reentry</strong>:&nbsp; Two electrical conduction pathways‚Äîtypically with different conduction characteristics‚Äîcreate conditions in which an impulse can travel down one pathway and then circle back retrogradely through the other (retrograde conduction), allowing for a reentrant pathway with a self-sustaining loop of electrical activity that can depolarize the myocardium repeatedly.&nbsp; Arrhythmias that develop due to reentry include AV nodal reentrant tachycardia (AVNRT), AV reentrant tachycardia (AVRT), atrial flutter, and most ventricular tachycardias.</li><li><strong>Increased automaticity</strong>:&nbsp; Phase 4 depolarization occurs more easily (eg, due to elevated sympathetic tone), creating foci of abnormal electrical activity.&nbsp; Arrhythmias that develop due to increased automaticity include atrial fibrillation, focal and multifocal atrial tachycardia, and some ventricular tachycardias.</li><li><strong>Triggered activity</strong>:&nbsp; Abnormal partial depolarizations occur and initiate arrhythmia.&nbsp; Arrhythmias that develop due to triggered activity include torsades de pointes (TdP).</li></ul><h2>Antiarrhythmic effects</h2><p>Antiarrhythmic drugs function by suppressing one or more of these 3 mechanisms.&nbsp; The mechanisms of class effects can be summarized as follows:</p><ul class=\"article-body-unordered-list\"><li>Class IA<ul class=\"article-body-unordered-list\"><li>Reduced action potential conduction velocity <strong>suppresses automaticity</strong>.</li><li>Increased action potential duration increases refractory period, which can both suppress automaticity and <strong>disrupt</strong> some types of <strong>reentrant circuits</strong>.</li><li>The effects are useful in the treatment of atrial fibrillation or flutter and some ventricular tachycardias.</li></ul></li><li>Class IB<ul class=\"article-body-unordered-list\"><li>Weak Na<font size=\"2\"><sup>+</sup></font> channel blockade creates a propensity for ischemic myocardium, making these drugs useful in treating <strong>ischemia-related ventricular tachycardia</strong>.</li><li>Class IB drugs are not useful in treating atrial arrhythmias.</li></ul></li><li>Class IC<ul class=\"article-body-unordered-list\"><li>Reduced action potential conduction velocity <strong>suppresses automaticity</strong>.</li><li>The effects are particularly useful in suppressing abnormal electrical foci responsible for atrial tachycardias (eg, atrial fibrillation) and in suppressing ventricular ectopy (eg, premature ventricular contractions).</li></ul></li><li>Class II<ul class=\"article-body-unordered-list\"><li>Reduced sympathetic activity to the myocardium <strong>suppresses automaticity</strong> and reduces the propensity for arrhythmogenic foci to develop.</li><li>The effects are particularly helpful in suppressing the abnormal electrical foci responsible for atrial tachycardias and some ventricular tachycardias.</li><li><strong>Slowed conduction</strong> through the AV node can also help treat some AV nodal-dependent reentrant arrhythmias (eg, AVNRT).</li></ul></li><li>Class III<ul class=\"article-body-unordered-list\"><li>Increased action potential duration increases refractory period, which can both <strong>suppress automaticity</strong> and <strong>disrupt</strong> some types of <strong>reentrant circuits</strong>.</li><li>The effects are particularly useful in disrupting the reentrant circuit responsible for most ventricular tachycardias and can sometimes be useful in suppressing the abnormal foci responsible for atrial tachycardias, including atrial fibrillation.</li></ul></li><li>Class IV<ul class=\"article-body-unordered-list\"><li>Inhibited Ca<font size=\"2\"><sup>2+</sup></font> influx <strong>slows conduction</strong> through the SA and AV nodes.</li><li>The effects can help treat some&nbsp; AV nodal‚Äìdependent arrhythmias.</li></ul></li></ul><h1>Summary of drugs used for specific indications</h1><p>The most common indications for the use of an antiarrhythmic drug include (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/126151.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">üìä</span> View Table: table 5\n                                    </a>\n                                </div>\n                                ):<p></p><ul class=\"article-body-unordered-list\"><li>Cardioversion of atrial fibrillation or flutter.</li><li>Maintenance of sinus rhythm in the setting of atrial fibrillation or flutter.</li><li>Treatment of ventricular tachycardia.</li><li>Suppression of ectopic atrial or ventricular activity.</li></ul><p>The choice of drug for rhythm control of atrial fibrillation in different clinical scenarios is largely driven by avoidance of serious adverse effects and is summarized here (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/36001.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">üìä</span> View Table: table 6\n                                    </a>\n                                </div>\n                                ).<p></p><h1>Adverse effects of antiarrhythmic drugs</h1><p>The use of antiarrhythmic drugs, particularly class I and class III drugs, is limited by adverse effects.&nbsp; Many of the adverse effects of antiarrhythmic drugs are driven by their class effect, whereas some adverse effects are drug specific.</p><h2>Class IA adverse effects&nbsp;</h2><ul class=\"article-body-unordered-list\"><li>TdP due to QT-interval prolongation (idiosyncratic effect, not dose related).</li><li>Drug-specific effects:<ul class=\"article-body-unordered-list\"><li>Procainamide:&nbsp; Drug-induced lupus.</li><li>Disopyramide:&nbsp; Anticholinergic effects (eg, dry mouth, constipation, urinary retention), decreased ventricular contractility.</li><li>Quinidine:&nbsp; Cinchonism, a syndrome of tinnitus, hearing loss, headache, visual disturbance, and flushing.</li></ul></li></ul><h2>Class IB adverse effects</h2><ul class=\"article-body-unordered-list\"><li>Neurologic symptoms, seizures.</li><li>Asystole and cardiac arrest if complete AV block is present (due to suppression of ventricular automaticity).</li></ul><h2>Class IC adverse effects</h2><ul class=\"article-body-unordered-list\"><li>Monomorphic ventricular tachycardia, particularly with ischemic or structural heart disease.</li></ul><h2>Class II adverse effects</h2><ul class=\"article-body-unordered-list\"><li>Bradycardia.</li><li>AV block.</li></ul><h2>Class III adverse effects</h2><ul class=\"article-body-unordered-list\"><li>TdP due to QT-interval prolongation.</li><li>Drug-specific effects:<ul class=\"article-body-unordered-list\"><li>Dofetilide:&nbsp; Renally cleared, therefore increased risk for toxicity with renal dysfunction.</li><li>Sotalol:&nbsp; Bradycardia, decreased ventricular contractility, renally cleared, therefore increased risk of toxicity with renal dysfunction.</li><li>Amiodarone:&nbsp; Numerous adverse effects unrelated to antiarrhythmic function (eg, thyroid, lung, and liver toxicity).</li></ul></li></ul><h2>Class IV adverse effects</h2><ul class=\"article-body-unordered-list\"><li>Bradycardia.</li><li>AV block.</li><li>Decreased ventricular contractility.</li><li>Constipation (impaired intestinal peristalsis).</li><li>Headache (vasodilation).</li></ul><p>The proarrhythmic adverse effects of antiarrhythmic drugs (driven by class effects) are summarized here (\n                                </p><div class=\"my-6\">\n                                    <a href=\"https://www.uworld.com/media/125336.html\" target=\"_blank\" class=\"glass-button w-full py-4 flex items-center justify-center text-white font-bold hover:scale-[1.02] transition-transform\">\n                                        <span class=\"mr-2\">üìä</span> View Table: table 7\n                                    </a>\n                                </div>\n                                ).<p></p><h1>Summary</h1><p>Antiarrhythmic drugs are classified by their primary mechanisms of action, each targeting specific phases of the cardiac action potential and influencing corresponding ECG intervals.&nbsp; Class I drugs block voltage-gated Na<font size=\"2\"><sup>+</sup></font> channels in nonpacemaker cells with varying strength and use dependence‚ÄîClass IA has moderate effects and prolongs the action potential, Class IB has a weak, rapidly dissociating blockade useful in ischemic myocardium, and Class IC has a strong, slow-dissociating blockade with high proarrhythmic risk in structural heart disease.&nbsp; Class II (beta blockers) and Class IV (nondihydropyridine Ca<font size=\"2\"><sup>2+</sup></font> channel blockers) reduce nodal automaticity and atrioventricular node conduction, prolonging the PR interval.&nbsp; Class III agents block K<font size=\"2\"><sup>+</sup></font> channels, prolonging repolarization and the QT interval.&nbsp; Certain drugs (eg, amiodarone, sotalol) exhibit mixed-class effects.&nbsp; Antiarrhythmic therapy targets the mechanisms underlying arrhythmias‚Äîreentry, increased automaticity, and triggered activity‚Äîand selection depends on arrhythmia type, underlying heart disease, and risk for adverse effects (eg, torsades de pointes, bradyarrhythmias).</p></div>\n            "
}